[
  {
    "ts": null,
    "headline": "Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?",
    "summary": "Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=ec4531fcb160ac354c66282576c87a6fcd9112a81652f91d1948f6be3196ef4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753884015,
      "headline": "Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?",
      "id": 136150037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=ec4531fcb160ac354c66282576c87a6fcd9112a81652f91d1948f6be3196ef4c"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Q2 Earnings Preview: What's in Store for the Stock?",
    "summary": "CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.",
    "url": "https://finnhub.io/api/news?id=35cf94ac279b2b77eada20a1fcffed3b966281ed98496395a6db0008c8fae749",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753878000,
      "headline": "Charles River Q2 Earnings Preview: What's in Store for the Stock?",
      "id": 136130399,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.",
      "url": "https://finnhub.io/api/news?id=35cf94ac279b2b77eada20a1fcffed3b966281ed98496395a6db0008c8fae749"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Formulation Development Outsourcing Forecast Report 2025-2033 Featuring SGS, Intertek, Recipharm, Lonza, Charles River Laboratories, Eurofins Scientific, Labcorp, Thermo Fisher Scientific",
    "summary": "The global Formulation Development Outsourcing Market is projected to grow from US$ 33.6 billion in 2024 to US$ 64.74 billion by 2033, at a CAGR of 7.56%. Key growth drivers include rising R&D costs, demand for specialized knowledge, complex regulations, and an expanding pharmaceutical industry. As pharmaceutical and biotech companies increasingly rely on contract development and manufacturing organizations (CDMOs) for integrated, end-to-end services, markets in North America, Europe, and the ra",
    "url": "https://finnhub.io/api/news?id=d5b478dc239482f4a68c45ce6a3fde2cb1632054ef994b3ec660d9a754d172df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753867560,
      "headline": "Pharma Formulation Development Outsourcing Forecast Report 2025-2033 Featuring SGS, Intertek, Recipharm, Lonza, Charles River Laboratories, Eurofins Scientific, Labcorp, Thermo Fisher Scientific",
      "id": 136129913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "The global Formulation Development Outsourcing Market is projected to grow from US$ 33.6 billion in 2024 to US$ 64.74 billion by 2033, at a CAGR of 7.56%. Key growth drivers include rising R&D costs, demand for specialized knowledge, complex regulations, and an expanding pharmaceutical industry. As pharmaceutical and biotech companies increasingly rely on contract development and manufacturing organizations (CDMOs) for integrated, end-to-end services, markets in North America, Europe, and the ra",
      "url": "https://finnhub.io/api/news?id=d5b478dc239482f4a68c45ce6a3fde2cb1632054ef994b3ec660d9a754d172df"
    }
  }
]